Cooper Companies (NASDAQ:COO – Get Free Report) issued its quarterly earnings data on Thursday. The medical device company reported $1.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.11, FiscalAI reports. Cooper Companies had a return on equity of 10.85% and a net margin of 5.57%.The firm had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter in the previous year, the company posted $0.96 EPS. The business’s revenue for the quarter was up 7.9% compared to the same quarter last year. Cooper Companies updated its FY 2026 guidance to 4.580-4.660 EPS.
Here are the key takeaways from Cooper Companies’ conference call:
- Record Q2 results came in ahead of expectations, with revenue up 8% to $1.08 billion and non-GAAP EPS up 26% to $1.21, marking the company’s tenth straight quarter of beating consensus.
- CooperSurgical strategic review is advancing after settlements resolved substantially all embryo media recall claims, and management said it is now in active discussions with multiple interested parties about the business.
- CooperVision strength was offset by Asia-Pac weakness: Americas and EMEA grew well, but Asia-Pac declined as the company continued to rationalize legacy hydrogel products and faced softer demand in Japan and China.
- Fertility performed strongly, with CooperSurgical fertility revenue up 10% organically, driven by capital equipment, RI Witness, and broader product demand; management expects mid-single-digit growth in the back half of the year.
- Free cash flow outlook improved to about $650 million for fiscal 2026, supported by inventory reductions from a new AI-based control system, though gross margins are expected to face pressure from FX, tariffs, freight, and lower production.
Cooper Companies Trading Up 8.6%
COO stock opened at $67.34 on Friday. The company has a market cap of $13.14 billion, a P/E ratio of 57.07, a PEG ratio of 1.60 and a beta of 0.87. Cooper Companies has a twelve month low of $58.89 and a twelve month high of $89.83. The company has a quick ratio of 0.79, a current ratio of 1.34 and a debt-to-equity ratio of 0.22. The business has a fifty day moving average of $65.09 and a 200-day moving average of $74.52.
Institutional Investors Weigh In On Cooper Companies
Wall Street Analyst Weigh In
Several equities analysts have issued reports on the company. Citigroup reiterated a “neutral” rating and issued a $69.00 price objective (down from $80.00) on shares of Cooper Companies in a research report on Thursday, May 28th. Stifel Nicolaus cut their price objective on Cooper Companies from $95.00 to $85.00 and set a “buy” rating for the company in a research report on Friday. Wall Street Zen upgraded Cooper Companies from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. JPMorgan Chase & Co. cut their price objective on Cooper Companies from $80.00 to $71.00 and set a “neutral” rating for the company in a research report on Friday. Finally, Piper Sandler set a $86.00 price objective on Cooper Companies and gave the company an “overweight” rating in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $82.64.
Trending Headlines about Cooper Companies
Here are the key news stories impacting Cooper Companies this week:
- Positive Sentiment: Cooper Companies posted better-than-expected Q2 results, with EPS of $1.21 topping estimates of $1.10 and revenue of $1.08 billion beating forecasts, while sales rose 7.9% year over year. CooperCompanies Announces Second Quarter 2026 Results
- Positive Sentiment: Management said it reached agreements to resolve substantially all claims tied to the prior fertility media recall, reducing a major legal overhang and supporting investor confidence in the company’s outlook. QuiverQuant article
- Positive Sentiment: Needham reaffirmed a Buy rating on COO and lowered its price target to $86, still implying meaningful upside from current levels. TipRanks analyst update
- Positive Sentiment: Stifel, Baird, and JPMorgan all cut price targets but kept constructive ratings, suggesting analysts see the report as solid even after valuation resets. Benzinga analyst update
- Neutral Sentiment: The company guided FY2026 EPS to $4.58-$4.66, slightly around consensus, which helps confirm expectations but does not point to a major near-term surprise. Earnings report transcript
- Negative Sentiment: JPMorgan lowered its price target on COO from $80 to $71 and kept a Neutral rating, reflecting more cautious expectations despite the stock’s recent strength. JPMorgan price target update
About Cooper Companies
Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.
The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.
Read More
- Five stocks we like better than Cooper Companies
- MarketBeat Week in Review – 06/01 – 06/05
- AI Server Earnings: Wall Street Sees One Clear Standout
- Navitas: NVIDIA’s AI Power Broker?
- A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.
